Pharmaceutical News

RSS

A drug that improves function of retinal blood vessels may be able to reduce the risk of stroke

The small study found that endothelial function is abnormal in eye blood vessels of patients who have early-stage hypertension, but that treatment with an angiotensin-receptor blocker (ARB) drug improves endothelial function. The endothelium is the lining of vessel walls and plays a key role in the vessels’ ability to relax and to constrict.

9 Apr 2004

Roche announces new dosing strategy

Roche has announced results from a study demonstrating that the new boosted dosing regimen for its protease inhibitor Invirase(R) (saquinavir 1000 mg with ritonavir 100 mg twice-daily) has no significant interactions when it is co-administered with tenofovir disoproxil fumarate (300 mg once-daily).

9 Apr 2004

Hepatitis C wonder drug Ribasphere gets approval from FDA

The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, “The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease.” Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. “Our aim is to bring affordable medicine to all individuals infected with this dreadful disease.” Mr. Kerrish continued.

8 Apr 2004

Unique heart arrhythmia drug represents one of the first molecular-based therapies for heart failure

Heart researchers at Columbia University Medical Center have developed and tested a unique heart arrhythmia drug that could prevent the sudden death of millions of people with heart failure as well as people with an inherited heart disorder. The drug represents one of the first molecular-based therapies for heart failure and avoids the toxicity of current treatments.

8 Apr 2004

Cinacalet helps control overactive thyroids, a major complication of advanced kidney disease

A new drug can help control an overactive thyroid, a major complication of advanced kidney disease, by playing a trick on the gland, a new study finds. The drug, cinacalet, is much more effective at keeping the parathyroid gland working normally than a placebo, according to the study. It may be a good alternative to standard therapy, researchers said.

7 Apr 2004

Research shows that intense high dose cholesterol lowering drugs result in a major reduction in deaths and severe heart attacks

If you want to increase your chances of living longer, taking cholesterol drugs is an easy way to do it. That's the message from a Harvard study of 4,162 people hospitalized in 350 places in eight countries. It is the first research to show that intense lowering of cholesterol results in a major reduction in deaths and severe heart attacks.

7 Apr 2004

Oral sildenafil improved exercise tolerance, cardiac output and quality of life in 22 patients with primary pulmonary hypertension

Oral sildenafil (Viagra®) improved exercise tolerance, cardiac output and quality of life in 22 patients with primary pulmonary hypertension, according to the results of the first randomized, placebo-controlled, double-blind, crossover study, reported in the April 7, 2004 issue of the Journal of the American College of Cardiology.

6 Apr 2004

Phase 3 study of drug teduglutide in patients with short bowel syndrome

Teduglutide is an analog of glucagon-like peptide 2 (GLP-2), a naturally occurring hormone that regulates the growth, proliferation and maintenance of cells lining the gastrointestinal tract. Teduglutide has been shown in animal studies and previous human clinical trials to increase the size and number of these cells, thereby increasing the absorptive surface area of the intestines.

6 Apr 2004

Collaboration to create a series of small molecule drugs leads against a Takeda target

Array BioPharma Inc. today announced the commencement of a drug discovery collaboration with Takeda Chemical Industries, Ltd. to create a series of small molecule drug leads against a Takeda target. This collaboration is in addition to Array's existing research agreement with Takeda that began in 2001.

5 Apr 2004

NeoRx Corporation acquires worldwide rights to platinum-based anti-cancer agent

NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.

5 Apr 2004

SkyePharma agreement with Medeus Pharma for marketing and distribution of DepoMorphine

SkyePharma PLC has announced that it has entered into a strategic marketing agreement with Medeus Pharma for the marketing and distribution of DepoMorphine(TM) in Europe. DepoMorphine(TM) is SkyePharma's novel sustained-release injectable formulation of morphine for relief of moderate-to-severe post-operative pain. DepoMorphine(TM) was filed in the US and Europe last year and approvals are anticipated to commence in the second half of 2004.

5 Apr 2004

New MRI Liver Contrast Agent Primovist(TM) Approved in Sweden

Schering AG Group, Germany has announced that the Swedish health authority MPA has granted marketing approval for its innovative liver imaging product Primovist(TM) (gadoxetic acid disodium). Primovist(TM) is designed for the detection and characterization of liver lesions by magnetic resonance imaging (MRI) including liver tumors, metastases as well as other malignant and benign lesions.

5 Apr 2004

AMA advises physicians to order influenza vaccine

In order to ensure the availability of influenza vaccine for administration early this coming fall, the AMA recommends that physicians and providers begin to order supplies of influenza vaccine immediately. In 2003, large numbers of cases of influenza began to appear in October, and activity was widespread.

5 Apr 2004

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad’ cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU’s mutual recognition procedure.

4 Apr 2004

Doctors Likelier to Delay Prescribing Antiretroviral Drugs for Women and Minority HIV Patients

A new UCLA study finds that doctors who follow guidelines recommending the delay of antiretroviral therapy for non-adherent HIV patients are likelier to put off that treatment for Latinos, women and poor patients than they do for others. In addition, doctors are slower to prescribe protease inhibitors for African American patients whether or not the physician follows the guidelines.

4 Apr 2004

GlaxoSmithKline and Theravance to form strategic alliance

GlaxoSmithKline plc (GSK) and Theravance, Inc., a privately-held pharmaceutical company, announced today that they have entered into an innovative broad-based strategic alliance to develop and commercialise novel medicines across a variety of important therapeutic areas, including bacterial infection, respiratory, urinary incontinence and gastrointestinal.

31 Mar 2004

Drug, Nembutal can suppress activity in colon cancer cells

A barbiturate once commonly used to treat anxiety may play a role in controlling the spread of colon cancer, say researchers from The University of Texas M. D. Anderson Cancer Center.

30 Mar 2004

FDA has approved Zyprexa, injectable anti-psychotic drug

Physicians have a new fast-acting option for controlling the potentially crippling effects of acute agitation in patients suffering with schizophrenia and bipolar mania. The U.S. Food and Drug Administration (FDA) has approved Zyprexa® IntraMuscular (olanzapine for injection), an injectable form of Lilly's top-selling medication.

30 Mar 2004

Aspirin surgery on neck arteries can prevent complications

Popping an aspirin the night before you are due to have surgery on neck arteries could help prevent a dangerous complication, a team of researchers at the University of Leicester has discovered.

30 Mar 2004

First Canadian therapeutic HIV vaccine trial

Clinicians from the McGill University Health Centre and the Centre hospitalier de l'Université de Montréal (CHUM) are participating in the first Canadian therapeutic HIV vaccine trial. Funded by a number of public and private institutions, including the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) and the Canadian Institutes of Health Research, this project will begin in April.

30 Mar 2004

Pharmaceutical News

A drug that improves function of retinal blood vessels may be able to reduce the risk of stroke

Roche announces new dosing strategy

Hepatitis C wonder drug Ribasphere gets approval from FDA

Unique heart arrhythmia drug represents one of the first molecular-based therapies for heart failure

Cinacalet helps control overactive thyroids, a major complication of advanced kidney disease

Research shows that intense high dose cholesterol lowering drugs result in a major reduction in deaths and severe heart attacks

Oral sildenafil improved exercise tolerance, cardiac output and quality of life in 22 patients with primary pulmonary hypertension

Phase 3 study of drug teduglutide in patients with short bowel syndrome

Collaboration to create a series of small molecule drugs leads against a Takeda target

NeoRx Corporation acquires worldwide rights to platinum-based anti-cancer agent

SkyePharma agreement with Medeus Pharma for marketing and distribution of DepoMorphine

New MRI Liver Contrast Agent Primovist(TM) Approved in Sweden

AMA advises physicians to order influenza vaccine

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

Doctors Likelier to Delay Prescribing Antiretroviral Drugs for Women and Minority HIV Patients

GlaxoSmithKline and Theravance to form strategic alliance

Drug, Nembutal can suppress activity in colon cancer cells

FDA has approved Zyprexa, injectable anti-psychotic drug

Aspirin surgery on neck arteries can prevent complications

First Canadian therapeutic HIV vaccine trial

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News